Loading
Cerus Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 25 Aug 2025.
Cerus Corp: what insiders have been doing
Cerus Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 14 insiders published 32 filings.
There is no open-market purchase to report; the filings show 10 sales worth €1.6M by 6 insiders. The totals do not cover 1 filing with an undisclosed amount. At €643k, the sale published on 16 March 2026 by Greenman William Mariner is the largest of the period.
With 32 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 12 purchases and 25 sales. The 10-K for the year ended 31 December 2025 shows 233.8 m USD of revenue and -15.6 m USD of net income.
The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
164
Thresholds
n/a
Buy Volume
€156,159
12 ops. · all time
Sell Volume
€3M
25 ops. · all time
Who traded when
BuySaleChrystal Jensen5 sales
Vivek K. Jayaraman4 sales
Dean A. Gregory2 buys
Eric Bjerkholt2 sales
Kevin Dennis Green2 sales
Richard J. Benjamin2 sales
+1 other insider
Since the insiders bought
- +106.0%Entry US$1.33 · Close at T+365 US$2.74
- -32.5%Entry US$2.00 · Close at T+365 US$1.35
- -22.0%Entry US$1.73 · Close at T+365 US$1.35
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,459 of 24,148 companies
33.5
score / 100
Value31
Quality36
FCF yld0.3%
Earn yld-3.6%
EV/EBITDA·
ROE-11%
Gross mgn54%
Net mgn-7.6%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.18
Analyst consensus
4 analysts1.00/5
US$4.00Target US$5.13(+135%)US$6.50
Income statement
RevenueUS$206.1M
Gross profitUS$112.3M54% margin
EBITDA-US$5.5M-3% margin
Net income-US$15.6M-3.1% margin
Valuation
PER (forward)-436.0x
P/Book6.3x
Beta1.83
Balance sheet & cash
Market capUS$439.3M
Total debtUS$96.9M
Free Cash FlowUS$1.1M
Debt / Equity109%
Profitability & ownership
ROE-10.8%
ROA-0.5%
% insiders3.6%
% institutions73.0%
Last declaration on 17 August 2026
Declarations164 total
30,000 shares@ US$2.98430.017% mcap100.0% of flowCommonSEC144:0001950047-26-008264
30,000 shares@ US$2.98430.017% mcap31.9% of flowCommon StockSEC:0001193125-26-354496:0
16,666 shares@ US$3.160.0099% mcap12.5% of flowCommon StockSEC:0001193125-26-309044:0
16,666 shares@ US$3.160.0099% mcap100.0% of flowCommonSEC144:0001950047-26-007149
20,454 sharesCommon StockSEC:0001193125-26-268227:0
20,454 shares@ US$2.60100.0% of flowCommonSEC144:0001950047-26-005807
16,667 shares@ US$3.000.011% mcap11.8% of flowCommon StockSEC:0001193125-26-254106:0
60,000 shares0Common StockSEC:0001193125-26-254116:0
60,000 shares0Common StockSEC:0001193125-26-254090:0
60,000 shares0Common StockSEC:0001193125-26-254094:0
60,000 shares0Common StockSEC:0001193125-26-254113:0
60,000 shares0Common StockSEC:0001193125-26-254120:0
200,000 shares0Common StockSEC:0001459351-26-000009:0
200,000 shares0Common StockSEC:0001564252-26-000008:0
165,200 shares@ US$1.657264.8% of flowCommon StockSEC:0001605456-26-000006:0
127,544 shares@ US$1.657221.6% of flowCommon StockSEC:0001459351-26-000007:0
447,757 shares@ US$1.657229.4% of flowCommon StockSEC:0001377258-26-000006:0
101,740 shares@ US$1.657219.6% of flowCommon StockSEC:0001296322-26-000009:0
113,008 shares@ US$1.657267.2% of flowCommon StockSEC:0001564252-26-000006:0
55,220 shares0Common StockSEC:0001296322-26-000007:0
80,320 shares0Common StockSEC:0001605456-26-000004:0
55,220 shares0Common StockSEC:0001564252-26-000004:0
63,854 shares0Common StockSEC:0001459351-26-000005:0
193,270 shares0Common StockSEC:0001377258-26-000004:0
25 of 164 declarations
About Cerus Corp
Cerus Corp. (Nasdaq: CERS) is a U.S.-listed healthcare technology company based in the United States, trading on the Nasdaq market. For international investors, it is best viewed as a focused, specialty blood-safety business rather than a broad-based pharmaceutical company. Cerus is dedicated primarily to improving the safety and availability of the world’s blood supply through pathogen-reduction technologies for transfused blood components. The company was incorporated in September 1991 and has built its commercial and regulatory platform around the INTERCEPT franchise. Its global headquarters is in Concord, California, with a European headquarters in Amersfoort, the Netherlands.
At the center of the business is the INTERCEPT Blood System, designed to inactivate certain pathogens in platelets and plasma. Cerus describes this platform as the only pathogen-reduction system with both CE mark and FDA approval for these two blood components. In the United States, the company also markets INTERCEPT for cryoprecipitation through INTERCEPT Fibrinogen Complex, a therapeutic product used to treat and control bleeding associated with fibrinogen deficiency, including major hemorrhage. In parallel, the INTERCEPT red blood cell system remains a late-stage clinical development program and is an important potential long-term growth driver.
Read moreShow less
Cerus holds a distinct competitive position in a highly specialized niche: transfusion safety. Its business model depends less on broad consumer demand and more on clinical adoption, regulatory approvals, and integration into blood-center workflows. Customers are primarily blood centers, hospitals, and transfusion-medicine institutions that value pathogen reduction as a safety and inventory-management tool. The company operates internationally, with commercial activity in the U.S., Europe, and selected other geographies. That global footprint broadens its opportunity set, but adoption remains dependent on regulatory pathways, reimbursement, and customer implementation cycles.
Recent developments have been constructive. In 2025 and early 2026, Cerus reported stronger product-revenue trends and reiterated growth expectations for 2026. Management also highlighted increasing global utilization of INTERCEPT-treated blood components, progress on the next-generation INT200 illumination device, and continued regulatory advancement in the red blood cell program, including a planned FDA submission over the medium term. The company has also benefited from U.S. Department of Defense funding tied to major-hemorrhage and trauma-care initiatives. For investors, Cerus is a specialized healthcare equity with meaningful regulatory optionality, recurring commercial execution, and a differentiated platform on the U.S. Nasdaq market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
